Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended
These findings suggest that low doses can still be effective, especially when paired with lifestyle changes like diet and exercise
Evidence shows that the secretion of incretin hormones may be impaired in some patients (particularly secretion of GLP-1 in obese individuals), but the major responsible factor is a loss of beta cell responsiveness to the incretin hormones [4]
Seven additional Phase 3 trials for retatrutide are expected to report results in 2026
How this fits the Hims & Hers Health narrative These launches line up closely with the long-term story of Hims & Hers as a platform for personalized, end-to-end care, not just a single-product GLP-1 player
Side effect tracking is a requirement for anyone on these medications
